Geoffrey D Barnes1, Yun Li2, Xiaokui Gu1, Brian Haymart1, Eva Kline-Rogers1, Mona A Ali3, Jay Kozlowski4, Gregory Krol5, James B Froehlich1, Scott Kaatz6. 1. Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI, USA. 2. School of Public Health, University of Michigan, Ann Arbor, MI, USA. 3. Department of Pharmacy, Beaumont Hospital, Royal Oak, MI, USA. 4. Department of Internal Medicine, Huron Valley Sinai Hospital, Commerce Township, MI, USA. 5. Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA. 6. Division of Hospital Medicine, Henry Ford Hospital, Detroit, MI, USA.
Abstract
BACKGROUND: Use of bridging anticoagulation increases a patient's bleeding risk without clear evidence of thrombotic prevention among warfarin-treated patients with atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin-treated patients with venous thromboembolism (VTE) has not been studied. METHODS: We identified warfarin-treated patients with VTE who temporarily stopped warfarin for a surgical procedure between 2010 and 2018 at six health systems. Using the 2012 American College of Chest Physicians guideline, we assessed use of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent VTE risk and 30-day outcomes (bleeding, thromboembolism, emergency department visit) were each assessed using logistic regression adjusted for multiple procedures per patient. RESULTS: During the study period, 789 warfarin-treated patients with VTE underwent 1529 procedures (median, 2; interquartile range, 1-4). Unadjusted use of bridging anticoagulation was more common in patients at high risk for VTE recurrence (99/171, 57.9%) than for patients at moderate (515/1078, 47.8%) or low risk of recurrence (134/280, 47.86%). Bridging anticoagulation use was higher in high-risk patients compared with low- or moderate-risk patients in both unadjusted (P = .013) and patient-level cluster-adjusted analyses (P = .031). Adherence to American College of Chest Physicians guidelines in high- and low-risk patients did not change during the study period (odds ratio, 0.98 per year; 95% confidence interval, 0.91-1.05). Adverse events were rare and not statistically different between the two treatment groups. CONCLUSIONS: Bridging anticoagulation was commonly overused among low-risk patients and underused among high-risk patients treated with warfarin for VTE. Adverse events were rare and not different between the two treatment groups.
BACKGROUND: Use of bridging anticoagulation increases a patient's bleeding risk without clear evidence of thrombotic prevention among warfarin-treated patients with atrial fibrillation. Contemporary use of bridging anticoagulation among warfarin-treated patients with venous thromboembolism (VTE) has not been studied. METHODS: We identified warfarin-treated patients with VTE who temporarily stopped warfarin for a surgical procedure between 2010 and 2018 at six health systems. Using the 2012 American College of Chest Physicians guideline, we assessed use of periprocedural bridging anticoagulation based on recurrent VTE risk. Recurrent VTE risk and 30-day outcomes (bleeding, thromboembolism, emergency department visit) were each assessed using logistic regression adjusted for multiple procedures per patient. RESULTS: During the study period, 789 warfarin-treated patients with VTE underwent 1529 procedures (median, 2; interquartile range, 1-4). Unadjusted use of bridging anticoagulation was more common in patients at high risk for VTE recurrence (99/171, 57.9%) than for patients at moderate (515/1078, 47.8%) or low risk of recurrence (134/280, 47.86%). Bridging anticoagulation use was higher in high-risk patients compared with low- or moderate-risk patients in both unadjusted (P = .013) and patient-level cluster-adjusted analyses (P = .031). Adherence to American College of Chest Physicians guidelines in high- and low-risk patients did not change during the study period (odds ratio, 0.98 per year; 95% confidence interval, 0.91-1.05). Adverse events were rare and not statistically different between the two treatment groups. CONCLUSIONS: Bridging anticoagulation was commonly overused among low-risk patients and underused among high-risk patients treated with warfarin for VTE. Adverse events were rare and not different between the two treatment groups.
Authors: James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Francis Couturaud; Olivier Sanchez; Gilles Pernod; Patrick Mismetti; Patrick Jego; Elisabeth Duhamel; Karine Provost; Claire Bal dit Sollier; Emilie Presles; Philippe Castellant; Florence Parent; Pierre-Yves Salaun; Luc Bressollette; Michel Nonent; Philippe Lorillon; Philippe Girard; Karine Lacut; Marie Guégan; Jean-Luc Bosson; Silvy Laporte; Christophe Leroyer; Hervé Décousus; Guy Meyer; Dominique Mottier Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: James D Douketis; Alex C Spyropoulos; Scott Kaatz; Richard C Becker; Joseph A Caprini; Andrew S Dunn; David A Garcia; Alan Jacobson; Amir K Jaffer; David F Kong; Sam Schulman; Alexander G G Turpie; Vic Hasselblad; Thomas L Ortel Journal: N Engl J Med Date: 2015-06-22 Impact factor: 91.245
Authors: Nathan P Clark; Daniel M Witt; Loren E Davies; Edward M Saito; Kathleen H McCool; James D Douketis; Kelli R Metz; Thomas Delate Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873
Authors: James D Douketis; Alex C Spyropoulos; Joanne Duncan; Marc Carrier; Gregoire Le Gal; Alfonso J Tafur; Thomas Vanassche; Peter Verhamme; Sudeep Shivakumar; Peter L Gross; Agnes Y Y Lee; Erik Yeo; Susan Solymoss; Jeannine Kassis; Geneviève Le Templier; Stephen Kowalski; Mark Blostein; Vinay Shah; Elizabeth MacKay; Cynthia Wu; Nathan P Clark; Shannon M Bates; Frederick A Spencer; Eleni Arnaoutoglou; Michiel Coppens; Donald M Arnold; Joseph A Caprini; Na Li; Karen A Moffat; Summer Syed; Sam Schulman Journal: JAMA Intern Med Date: 2019-11-01 Impact factor: 21.873